Cancellation and Grant of Options

RNS Number : 5155Q

Destiny Pharma PLC

19 June 2020

 

 19 June 2020

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Cancellation and Grant of Options

Brighton, United Kingdom - 19 June 2020 -   Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that on 18 June 2020, the Company cancelled options over 150,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") (representing 0.34 per cent. of the Company's issued share capital) in respect of the below Director. 

Name	Position	Options Cancelled	Total Options Held Post Cancellation
Shaun Claydon	Chief Financial Officer	150,000	150,000

The cancelled options represent awards under the Destiny Pharma Employee Long Term Incentive Plan 2018, approved by the Company on 25 January 2018 for EMI and non-tax advantage options.

Further to this, the Company today granted options ("Options") over 165,000 new Ordinary Shares (representing 0.38 per cent. of the Company's issued share capital) to the below Director and PDMR. 

Name	Position	Options Issued	Total Options Held Post Issue
Shaun Claydon	Chief Financial Officer	125,000	275,000
Jesus Gonzales	PDMR	40,000	115,000

The Options represent awards under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on 25 January 2018 for EMI and non-tax advantage options. All Options granted above have an exercise price of 0.01 per Ordinary Share and for Shaun Claydon the Options will vest on 26 October 2021. The Options granted to Jesus Gonzales will vest on 19 June 2023. Both Option grants are exercisable for ten years after the date of grant.

For further information, please contact: 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[e-mail]

[phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

[e-mail]

[phone]

finnCap Ltd  (Nominated Adviser and Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners  (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma 

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit  https://www.destinypharma.com  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Claydon
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options over ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Cancellation of Options
c)	Price(s) and volume(s)	76.5 pence per Ordinary Share 150,000 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	18 June 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Claydon
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options over ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of Options
c)	Price(s) and volume(s)	1 pence per Ordinary Share 125,000 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	19 June 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jesus Gonzales
2.	Reason for the Notification
a)	Position/status	Chief Medical Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options over ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of Options
c)	Price(s) and volume(s)	1 pence per Ordinary Share 40,000 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	19 June 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

DSHUKVKRRBUNARR